Among patients with CCA and FGFR2 gene fusions treated with selective FGFR inhibitors, secondary FGFR2 kinase domain mutations are detected in up to 60% of cases, either from post progression ctDNA or tissue biopsy.102. Here, FGFR2 is linked to cholangiocarcinoma.